You are here: Home: BCU 6 | 2006: Panel Discussion: Select publications


Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.

Burstein HJ et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. San Antonio Breast Cancer Symposium 2002;446. No abstract available

Carlini P et al. Exemestane (EXE) is an effective 3rd-line hormonal therapy for postmenopausal metastatic breast cancer (MBC) patients (pts) pretreated with 3rd generation non steroidal aromatase inhibitors (nSAI). Ann Oncol 2002;13(Suppl 5):48. Abstract

Ghosn M et al. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006;26(3B):2451-6. Abstract

Martin LA et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278(33):30458-68. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005b;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005c;23(4):792-9. Abstract

Nole F et al. Capecitabine/vinorelbine: An effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 2006;6(6):518-24. Abstract

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

Perey L et al. Fulvestrant (Faslodex) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial. Breast Cancer Res Treat 2004;88(Suppl 1):236;Abstract 6048.

Thürlimann B et al. Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 — A sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85(3):247- 54. Abstract

BCU Think Tank

CME Test Online

Home · Search

Editor’s Note:
Reality check

Marc E Lippman, MD
- Select publications

C Kent Osborne, MD
- Select publications

I Craig Henderson, MD
- Select publications

Charles E Geyer Jr, MD
- Select publications

Frank A Vicini, MD
- Select publications

Miami Beach Cancer Conference Tumor Panel Discussion on Systemic Therapy of Metastatic Disease
- Select publications

CME Information

Faculty Disclosures

Editor's Office

Media Center
Media Center
Previous Editions